Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma

被引:13
作者
Kim, Hye Soo [2 ]
Kim, Jong Ok [3 ]
Lee, Dong Ho [4 ]
Lee, Han Chul [1 ]
Kim, Hee Jin [1 ]
Kim, Jeong Hwan [1 ]
Jang, Yi Sun [2 ]
Lee, Jong Min [2 ]
Kim, Seon Young [1 ]
Kim, Yong Sung [1 ]
机构
[1] KRIBB, Med Genom Res Ctr, Taejon 305806, South Korea
[2] Catholic Univ Korea, Dept Internal Med, Coll Med, Taejon 301723, South Korea
[3] Catholic Univ Korea, Dept Pathol, Coll Med, Taejon 301723, South Korea
[4] Catholic Univ Korea, Dept Surg, Coll Med, St Marys Hosp, Taejon 301723, South Korea
关键词
papillary thyroid carcinoma; BRAF mutation; LCM; pyrosequencing; BRAF(V600E) MUTATION; KOREAN PATIENTS; CANCER; MICROCARCINOMA; DIAGNOSIS; SPECIMENS; NODULES; REFINES; RET/PTC; V600E;
D O I
10.3892/or.2011.1225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The BRAF T1799A mutation is a heterozygous point mutation and its reported prevalence in papillary thyroid carcinoma (PTC) has varied from 29 to 83%, with an overall mean of 44%. In Korea, the reported mutation rate reached 83% in PTC and 52% in micropapillary carcinoma. We hypothesized that the differences in prevalence may be influenced by the methods of mutation analysis, the sizes of tumor and ethnic differences. Three types of DNA samples from the same PTC mass (0.4-1.6 cm, mean 0.83 cm sized) per each patient (n=17) were isolated. The first type was obtained from frozen PTC tissues using laser-captured microdissection (Frozen-laser, n=17), the second was obtained from frozen tissue by manual tumor margin dissection using a blade (Frozen-blade, n=17) and the third was obtained from formalin-fixed, paraffin-embedded tissue by manual margin dissection (Paraffin-blade, n=15, 2 failed). The mutation rates of the three-matched DNA samples were compared by the SNP mode and AQ mode of pyrosequencing, and direct DNA sequencing. Both the AQ mode of pyrosequencing and the direct DNA sequencing detected the BRAF T1799A mutation in 100% of the 'Frozen-laser' samples, but the mutation was omitted in 1/17 of the 'Frozen-blade' samples and in 5/15 of the 'Paraffin-blade' samples, while the former was more rapid and objective than the latter. The SNP mode of pyrosequencing variably detected the mutation from 40 to 100%, and it showed the lowest sensitivity. Our results indicate that the reported prevalence of the BRAF T1799A mutation in PTC can be underestimated due the mutation analysis methods, and especially in small PTCs. The BRAF T1799A mutation may be an early and essential carcinogenic event in nearly all Korean PTCs, and even in micro-PTCs. For the accurate detection of the BRAF T1799A mutation from small PTCs, fresh or frozen tissues and more cautious microdissection are required, and the AQ mode of pyrosequencing assay is preferred.
引用
收藏
页码:1639 / 1644
页数:6
相关论文
共 26 条
[1]   Papillary microcarcinoma of the thyroid - Prognostic significance of lymph node metastasis and multifocality [J].
Chow, SM ;
Law, SCK ;
Chan, JKC ;
Au, SK ;
Yau, S ;
Lau, WH .
CANCER, 2003, 98 (01) :31-40
[2]   Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area [J].
Chung, Ki-Wook ;
Yang, Sun Kyung ;
Lee, Geon Kook ;
Kim, Eun Young ;
Kwon, Soim ;
Lee, Sang Hyun ;
Park, Do Joon ;
Lee, Hyun Sook ;
Cho, Bo Youn ;
Lee, Eun Sook ;
Kim, Sun Wook .
CLINICAL ENDOCRINOLOGY, 2006, 65 (05) :660-666
[3]   Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid:: A potential application for the preoperative assessment of thyroid nodules [J].
Cohen, Y ;
Rosenbaum, E ;
Clark, DP ;
Zeiger, MA ;
Umbricht, CB ;
Tufano, RP ;
Sidransky, D ;
Westra, WH .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2761-2765
[4]  
Coombs N J, 1999, Nucleic Acids Res, V27, pe12, DOI 10.1093/nar/27.16.e12
[5]  
Cooper DS, 2009, THYROID, V19, P1, DOI DOI 10.1089/THY.2009.0110
[6]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[7]   Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].
Davies, L ;
Welch, HG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167
[8]   Targeting BRAF in thyroid cancer [J].
Espinosa, A. V. ;
Porchia, L. ;
Ringel, M. D. .
BRITISH JOURNAL OF CANCER, 2007, 96 (01) :16-20
[9]   Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].
Flaherty, Keith T. ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
O'Dwyer, Peter J. ;
Lee, Richard J. ;
Grippo, Joseph F. ;
Nolop, Keith ;
Chapman, Paul B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819
[10]   A rapid and simple detection method for the BRAFTI796A mutation in fine-needle aspirated thyroid carcinoma cells [J].
Hayashida, N ;
Namba, H ;
Kumagai, A ;
Hayashi, T ;
Ohtsuru, A ;
Ito, M ;
Saenko, VA ;
Maeda, S ;
Kanematsu, T ;
Yamashita, S .
THYROID, 2004, 14 (11) :910-915